S 
Samsung Biologics Co 207940.KS · KRW
Health Care · Life Sciences Tools & Services · KRX · 🇰🇷 South Korea
1,510,000
-0.40%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in KRW, from our data supplier.
Revenue
₩4.56trn
FY2016FY2025
Net income
₩1.78trn
FY2016FY2025
Free cash flow
₩772.73bn
FY2016FY2025
Shareholders' equity
₩7.45trn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₩4.56trn | ₩3.50trn | ₩3.69trn | ₩3.00trn | ₩1.57trn | ₩1.16trn | ₩701.59bn | ₩535.81bn | ₩464.63bn | ₩294.62bn |
| Research and development | ₩37.18bn | ₩36.71bn | ₩81.59bn | ₩45.88bn | ₩954.2m | ₩5.11bn | — | — | — | — |
| Operating income | ₩2.07trn | ₩1.32trn | ₩1.11trn | ₩983.63bn | ₩537.31bn | ₩292.79bn | ₩91.74bn | ₩55.68bn | ₩65.98bn | −₩30.42bn |
| Net income | ₩1.78trn | ₩1.08trn | ₩857.69bn | ₩798.06bn | ₩393.59bn | ₩240.97bn | ₩202.90bn | ₩224.11bn | −₩96.97bn | −₩176.82bn |
| Diluted earnings per share | 26,968.22 | 16,372.94 | 12,962.92 | 12,061.61 | 5,948.61 | 3,642.03 | 3,066.64 | 7,476.14 | -1,468.84 | -2,672.46 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | ₩11.06trn | ₩17.34trn | ₩16.05trn | ₩16.58trn | ₩7.97trn | ₩6.42trn | ₩5.91trn | ₩5.98trn | ₩7.18trn | ₩7.53trn |
| Total liabilities | ₩3.61trn | ₩6.43trn | ₩6.22trn | ₩7.60trn | ₩2.98trn | ₩1.83trn | ₩1.56trn | ₩1.82trn | ₩3.21trn | ₩3.45trn |
| Debt | ₩599.01bn | ₩1.49trn | ₩1.91trn | ₩2.51trn | ₩1.29trn | ₩784.91bn | ₩653.71bn | ₩872.70bn | ₩545.91bn | ₩843.06bn |
| Shareholders' equity | ₩7.45trn | ₩10.90trn | ₩9.83trn | ₩8.98trn | ₩4.99trn | ₩4.60trn | ₩4.35trn | ₩4.16trn | ₩3.98trn | ₩4.08trn |
| Shares outstanding | 66m | 66m | 66m | 66m | 66m | 66m | 66m | 30m | 66m | 66m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | ₩2.25trn | ₩1.66trn | ₩1.67trn | ₩953.05bn | ₩454.60bn | ₩202.09bn | ₩10.15bn | −₩33.02bn | ₩149.82bn | −₩62.66bn |
| Capital spending | −₩1.48trn | −₩1.38trn | −₩1.11trn | −₩956.84bn | −₩406.25bn | −₩139.66bn | −₩192.84bn | −₩278.65bn | −₩494.12bn | −₩168.17bn |
| Free cash flow | ₩772.73bn | ₩281.73bn | ₩560.90bn | −₩3.79bn | ₩48.34bn | ₩62.43bn | −₩182.68bn | −₩311.66bn | −₩344.30bn | −₩230.83bn |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩1.32trn | ₩1.26trn | ₩308.57bn | ₩1.66trn | ₩1.01trn | ₩999.54bn | ₩1.26trn | ₩1.19trn |
| Operating income | ₩586.44bn | ₩580.75bn | ₩378.08bn | ₩728.85bn | ₩477.20bn | ₩430.24bn | ₩384.38bn | ₩338.58bn |
| Net income | ₩430.65bn | ₩469.25bn | ₩509.95bn | ₩574.46bn | ₩324.39bn | ₩375.55bn | ₩321.49bn | ₩264.47bn |
| Diluted earnings per share | 6,508.79 | 7,092.05 | 7,707.29 | 8,682.23 | 4,902.69 | 5,676.02 | 4,858.97 | 3,997.10 |
| Cash from operations | ₩624.80bn | ₩767.68bn | ₩422.15bn | ₩619.30bn | ₩523.38bn | ₩682.98bn | ₩389.56bn | ₩740.39bn |
| Capital spending | −₩99.08bn | −₩91.52bn | −₩554.84bn | −₩113.81bn | −₩156.81bn | −₩649.61bn | −₩572.56bn | −₩570.51bn |
| Free cash flow | ₩525.73bn | ₩676.16bn | −₩132.69bn | ₩505.48bn | ₩366.57bn | ₩33.37bn | −₩183.00bn | ₩169.88bn |
| Total assets | ₩12.65trn | ₩11.99trn | ₩11.06trn | ₩18.34trn | ₩17.77trn | ₩17.44trn | ₩17.34trn | ₩16.03trn |
| Debt | ₩599.23bn | ₩599.10bn | ₩599.01bn | ₩893.40bn | ₩1.06trn | ₩1.06trn | ₩1.01trn | ₩214.83bn |
| Shareholders' equity | ₩8.36trn | ₩7.92trn | ₩7.45trn | ₩12.18trn | ₩11.60trn | ₩11.28trn | ₩10.90trn | ₩10.59trn |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 14.9% | 31.4% | 47.9% |
| Operating income | 28.1% | 47.9% | — |
| Net income | 30.8% | 49.2% | -0.7% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Operating margin | 42.1% | 37.2% | 36.1% | 32.2% |
| Net margin | 35.6% | 30.7% | 29.5% | 36.9% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 62.9 | 89.1 | 90.1 | 104.7 | 230.9 | 345.1 | 214.8 | 78.7 | -384.3 | -86.0 |
| Price to sales | 24.6 | 27.6 | 20.9 | 27.8 | 58.0 | 71.4 | 62.1 | 32.9 | 80.2 | 51.6 |
Dividends and splits
Per share, in the currency the company pays
Paid for 0 years.
- 1-to-0.650391 reverse split · 30 Oct 2025
- 1-to-0.650391 reverse split · 29 Sept 2025
- 476-for-471 split · 28 Feb 2022
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.